Changes to listings for ROSIGLITAZONE MALEATE (Avandia®) and ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE (Avandamet®)

1 November 2008

The Pharmaceutical Benefits Scheme (PBS) listings for ROSIGLITAZONE MALEATE (Avandia®) and ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE (Avandamet®) are as follows:

Removal of the following ROSIGLITAZONE subsidies from the PBS:  

• As of 01 October 2008 - ROSIGLITAZONE for the initiation or continuation of combination therapy with insulin (streamlined authority codes 2730 and 2731)
• As of 01 November 2008 - ROSIGLITAZONE for the initiation of triple oral combination therapy with metformin and a sulfonylurea (streamlined authority codes 2648 (ROSIGLITAZONE MALEATE), 2634 (ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE))
• As of 1 February 2009 - ROSIGLITAZONE for continuation of therapy for patients who have previously received and been stabilised on a PBS-subsidised regimen of oral combination therapy with metformin and sulfonylurea (streamlined authority code 3037 (for both ROSIGLATIZONE MALEATE and ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE))

Unchanged ROSIGLITAZONE subsidy on the PBS:

• Dual oral combination therapy with metformin or a sulfonylurea (streamlined authority codes 2635 (ROSIGLITAZONE MALEATE) and 2633 (ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE))